In lieu of all the chatter and bantering about whether they should've issued a PR for last patient injected, uplisting, to RS or not, etc....I've been thinking about how I think this will unfold and here's my opinion:
I think that they will issue a PR for combo results very close to the share holders meeting on 8/25. We will see a nice little pop in the SP but not enough to uplist (my guess is $1.20-1.35 share). Within a couple days, and before the SP can get hammered back down, management will do the "friendliest to share holders" RS in the form of 2:1, which will put us above $2 and we hit the NYSE. After a couple more days, they issue another PR updating mono enrollment and /or updating FDA meeting scheduled etc.
They have to keep the momentum going to keep the SP from dropping again or being shorted. They also have to bring in big dollar investors and the only way to do that is uplist. I've stated I'm not a fan of the RS, but I still think that may happen here. If so, I can only hope it's 2:1 or 3:1 at the most. My point is they cannot let their foot off the gas pedal once they issue the first piece of good news. These next few weeks will be very interesting!!
Just throwing that out there to see what others think. Do you guys feel that with very good results that we can get above $2/share without an RS? Do you think we can get there with just one PR for combo results?
